Clinical Research Article | Published:

Urinary acute kidney injury biomarkers in very low-birth-weight infants on indomethacin for patent ductus arteriosus

Pediatric Research (2019) | Download Citation

Subjects

Abstract

Background

Serum creatinine (SCr)- or urine output-based definitions of acute kidney injury (AKI) have important limitations in neonates. This study evaluates the diagnostic value of urinary biomarkers in very low-birth-weight (VLBW) infants receiving indomethacin for closure of a patent ductus arteriosus (PDA).

Methods

Prospective cohort study in 14 indomethacin-treated VLBW infants and 18 VLBW infants without indomethacin as controls. Urinary biomarkers were measured before, during, and after indomethacin administration.

Results

Indomethacin therapy was associated with significantly higher SCr concentrations at 36, 84, and 120 h compared to controls. At 36 h, three indomethacin-treated patients met the criteria for neonatal modified Kidney Disease: Improving Global Outcomes (KDIGO) AKI. The product of urinary tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7 ([TIMP-2]•[IGFBP7]) was significantly elevated in the AKI subgroup at 12 h (P < 0.05), hence 24 h earlier than the increase in SCr. Urinary neutrophil gelatinase-associated lipocalin (NGAL) and calprotectin were significantly increased in the indomethacin group at 12 h (P < 0.05), irrespective of fulfillment of the AKI criteria. Urinary kidney injury molecule-1 (KIM-1) was not significantly altered.

Conclusion

While urinary [TIMP-2]•[IGFBP7] proves valuable for the early diagnosis of neonatal modified KDIGO-defined AKI, elevated urinary NGAL and calprotectin concentrations in indomethacin-treated VLBW infants not fulfilling the AKI criteria may indicate subclinical kidney injury.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  1. 1.

    Hanna, M. H., Askenazi, D. J. & Selewski, D. T. Drug-induced acute kidney injury in neonates. Curr. Opin. Pediatr. 28, 180–187 (2016).

  2. 2.

    Selewski, D. T. et al. Neonatal acute kidney injury. Pediatrics 136, e463–e473 (2015).

  3. 3.

    Kent, A. L. et al. Renal glomeruli and tubular injury following indomethacin, ibuprofen, and gentamicin exposure in a neonatal rat model. Pediatr. Res. 62, 307–312 (2007).

  4. 4.

    Schreuder, M. F. et al. Effect of drugs on renal development. Clin. J. Am. Soc. Nephrol. 6, 212–217 (2011).

  5. 5.

    Ohlsson, A., Walia, R. & Shah S. S. Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants. Cochrane Database Syst. Rev. Issue 2. Art. No.: CD003481 (2015).

  6. 6.

    Bateman, D. A. et al. Serum creatinine concentration in very-low-birth-weight infants from birth to 34–36 wk postmenstrual age. Pediatr. Res. 77, 696–702 (2015).

  7. 7.

    Guignard, J. P. & Drukker, A. Why do newborn infants have a high plasma creatinine? Pediatrics 103, e49 (1999).

  8. 8.

    McCaffrey, J., Dhakal, A. K., Milford, D. V., Webb, N. J. & Lennon, R. Recent developments in the detection and management of acute kidney injury. Arch. Dis. Child. 102, 91–96 (2017).

  9. 9.

    Schrezenmeier, E. V., Barasch, J., Budde, K., Westhoff, T. & Schmidt-Ott, K. M. Biomarkers in acute kidney injury—pathophysiological basis and clinical performance. Acta Physiol. (Oxf.). 219, 554–572 (2017).

  10. 10.

    Askenazi, D. J. et al. Acute kidney injury urine biomarkers in very low-birth-weight infants. Clin. J. Am. Soc. Nephrol. 11, 1527–1535 (2016).

  11. 11.

    Genc, G., Ozkaya, O., Avci, B., Aygun, C. & Kucukoduk, S. Kidney injury molecule-1 as a promising biomarker for acute kidney injury in premature babies. Am. J. Perinatol. 30, 245–252 (2013).

  12. 12.

    Lavery, A. P. et al. Urinary NGAL in premature infants. Pediatr. Res. 64, 423–428 (2008).

  13. 13.

    Sarafidis, K. et al. Urine neutrophil gelatinase-associated lipocalin to predict acute kidney injury in preterm neonates. A pilot study. Pediatr. Nephrol. 29, 305–310 (2014).

  14. 14.

    Tabel, Y. et al. Urinary neutrophil gelatinase-associated lipocalin as an early biomarker for prediction of acute kidney injury in preterm infants. Am. J. Perinatol. 31, 167–174 (2014).

  15. 15.

    Sweetman, D. U. Neonatal acute kidney injury—severity and recovery prediction and the role of serum and urinary biomarkers. Early Hum. Dev. 105, 57–61 (2017).

  16. 16.

    Heller, F., Frischmann, S., Grunbaum, M., Zidek, W. & Westhoff, T. H. Urinary calprotectin and the distinction between prerenal and intrinsic acute kidney injury. Clin. J. Am. Soc. Nephrol. 6, 2347–2355 (2011).

  17. 17.

    Westhoff, J. H. et al. Urinary biomarkers for the differentiation of prerenal and intrinsic pediatric acute kidney injury. Pediatr. Nephrol. 31, 2353–2363 (2016).

  18. 18.

    Vijayan, A. et al. Clinical use of the urine biomarker [TIMP-2] x [IGFBP7] for acute kidney injury risk assessment. Am. J. Kidney Dis. 68, 19–28 (2016).

  19. 19.

    Sperandio, M. et al. Effectiveness and side effects of an escalating, stepwise approach to indomethacin treatment for symptomatic patent ductus arteriosus in premature infants below 33 weeks of gestation. Pediatrics 116, 1361–1366 (2005).

  20. 20.

    Kellum, J. A., Lameire, N. & Group KAGW. Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1). Crit. Care 17, 204 (2013).

  21. 21.

    Westhoff, J. H. et al. Urinary tissue inhibitor of metalloproteinase-2 (TIMP-2) * insulin-like growth factor-binding protein 7 (IGFBP7) predicts adverse outcome in pediatric acute kidney injury. PLoS ONE 10, e0143628 (2015).

  22. 22.

    Seibert, F. S. et al. Calprotectin and neutrophil gelatinase-associated lipocalin in the differentiation of pre-renal and intrinsic acute kidney injury. Acta Physiol. (Oxf.). 207, 700–708 (2013).

  23. 23.

    Akima, S., Kent, A., Reynolds, G. J., Gallagher, M. & Falk, M. C. Indomethacin and renal impairment in neonates. Pediatr. Nephrol. 19, 490–493 (2004).

  24. 24.

    Haase, M. et al. The outcome of neutrophil gelatinase-associated lipocalin-positive subclinical acute kidney injury: a multicenter pooled analysis of prospective studies. J. Am. Coll. Cardiol. 57, 1752–1761 (2011).

  25. 25.

    Allegaert, K., De Hoon, J., Debeer, A. & Gewillig, M. Renal side effects of non-steroidal anti-inflammatory drugs in neonates. Pharmaceuticals (Basel) 3, 393–405 (2010).

  26. 26.

    Kashani, K. et al. Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury. Crit. Care 17, R25 (2013).

  27. 27.

    Kuribayashi, R. et al. Urinary neutrophil gelatinase-associated lipocalin is an early predictor of acute kidney injury in premature infants. Exp. Ther. Med. 12, 3706–3710 (2016).

  28. 28.

    Parravicini, E. The clinical utility of urinary neutrophil gelatinase-associated lipocalin in the neonatal ICU. Curr. Opin. Pediatr. 22, 146–150 (2010).

  29. 29.

    Sellmer, A. et al. Urinary neutrophil gelatinase-associated lipocalin in the evaluation of patent ductus arteriosus and AKI in very preterm neonates: a cohort study. BMC Pediatr. 17, 7 (2017).

  30. 30.

    Tosse, V. et al. Urinary NT-proBNP, NGAL, and H-FABP may predict hemodynamic relevance of patent ductus arteriosus in very low birth weight infants. Neonatology 101, 260–266 (2012).

  31. 31.

    Fujiu, K., Manabe, I. & Nagai, R. Renal collecting duct epithelial cells regulate inflammation in tubulointerstitial damage in mice. J. Clin. Invest. 121, 3425–3441 (2011).

  32. 32.

    Dessing, M. C. et al. The calcium-binding protein complex S100A8/A9 has a crucial role in controlling macrophage-mediated renal repair following ischemia/reperfusion. Kidney Int. 87, 85–94 (2015).

  33. 33.

    McCullough, P. A. et al. Diagnosis of acute kidney injury using functional and injury biomarkers: workgroup statements from the tenth Acute Dialysis Quality Initiative Consensus Conference. Contrib. Nephrol. 182, 13–29 (2013).

  34. 34.

    Endre, Z. H. et al. Differential diagnosis of AKI in clinical practice by functional and damage biomarkers: workgroup statements from the tenth Acute Dialysis Quality Initiative Consensus Conference. Contrib. Nephrol. 182, 30–44 (2013).

  35. 35.

    Lee, B. S. et al. Effect of furosemide on ductal closure and renal function in indomethacin-treated preterm infants during the early neonatal period. Neonatology 98, 191–199 (2010).

  36. 36.

    Fiseha, T. & Tamir, Z. Urinary markers of tubular injury in early diabetic nephropathy. Int. J. Nephrol. 2016, 4647685 (2016).

  37. 37.

    Koralkar, R. et al. Acute kidney injury reduces survival in very low birth weight infants. Pediatr. Res. 69, 354–358 (2011).

  38. 38.

    Parry, G., Tucker, J., Tarnow-Mordi, W. & Group UKNSSC. CRIB II: an update of the clinical risk index for babies score. Lancet 361, 1789–1791 (2003).

  39. 39.

    Huynh, T. K. et al. Reference values of urinary neutrophil gelatinase-associated lipocalin in very low birth weight infants. Pediatr. Res. 66, 528–532 (2009).

  40. 40.

    Vinall, J. & Grunau, R. E. Impact of repeated procedural pain-related stress in infants born very preterm. Pediatr. Res. 75, 584–587 (2014).

Download references

Acknowledgements

We thank all nurses of the NICU for their diligence in collecting samples. We also thank Simone Voigt for her indefatigable efforts in this study. We are indebted to all parents of our tiny patients who gave their consent to have their children participate in this study. The study was funded by the German Research Foundation (Research Unit FOR1368). NephroCheck® Test Kits and the Astute 140® Meter were kindly provided by Astute Medical (San Diego, CA, USA). ARCHITECT® Urine NGAL assays were kindly provided by Abbott Diagnostics (Abbott Laboratories, Abbott Park, IL, USA).

Author information

Author notes

  1. These authors contributed equally: Sina Waldherr, Alexander Fichtner

Affiliations

  1. Department of Neonatology, University Children’s Hospital, Heidelberg, Germany

    • Sina Waldherr
    • , Bernd Beedgen
    •  & Johannes Pöschl
  2. Department of Pediatrics I, University Children’s Hospital, Heidelberg, Germany

    • Alexander Fichtner
    • , Franz Schaefer
    • , Burkhard Tönshoff
    •  & Jens H. Westhoff
  3. Institute of Medical Biometry and Informatics, University of Heidelberg, Heidelberg, Germany

    • Thomas Bruckner
  4. Medical Department I, Marien Hospital Herne, University Hospital of the Ruhr-University of Bochum, Herne, Germany

    • Timm H. Westhoff

Authors

  1. Search for Sina Waldherr in:

  2. Search for Alexander Fichtner in:

  3. Search for Bernd Beedgen in:

  4. Search for Thomas Bruckner in:

  5. Search for Franz Schaefer in:

  6. Search for Burkhard Tönshoff in:

  7. Search for Johannes Pöschl in:

  8. Search for Timm H. Westhoff in:

  9. Search for Jens H. Westhoff in:

Contributions

A.F., S.W., and J.H.W. conceived and designed the experiments. S.W., A.F., B.B., T.H.W., and J.H.W. performed the experiments. S.W., A.F., T.B., F.S., B.T., J.P., T.H.W., and J.H.W. analyzed the data or interpreted the results. J.H.W. wrote the draft of the article. A.F., S.W., B.T., and T.H.W. edited the manuscript. All other authors approved the manuscript to be published.

Competing interests

The authors declare no competing interests.

Corresponding author

Correspondence to Jens H. Westhoff.

Supplementary information

About this article

Publication history

Received

Revised

Accepted

Published

DOI

https://doi.org/10.1038/s41390-019-0332-9